Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction

In this economic evaluation, based on current cost-effectiveness benchmarks, empagliflozin provides low economic value compared with standard of care for HFpEF, largely due to its lack of efficacy on mortality and small benefit on quality of life.